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achieving seizure freedom even after having failed several AEDs. 5, [9] [10] [11] Although withdrawal of ineffective drugs, when given as first or subsequent treatments, is usually clearly documented, the information becomes fragmentary regarding the reasons for discontinuation. Additionally, with some exceptions, [12] [13] [14] AED retention has not been assessed in a population-based sample. Lastly, there are no data on the history of AED treatment in samples of children and adults with epilepsy from the same population and followed for a prolonged period of time.
We investigated rate, reasons, and predictors of AED discontinuations in a well-defined population followed for up to 20 years from treatment start. We aimed: (1) to estimate the retention rate of AEDs according to the order of administration (first, second, or subsequent) in general and by drug; (2) to investigate the reasons for stopping AEDs with reference to the sequence of drug assignment; and (3) to ascertain possible predictors of treatment discontinuation with reference to the commonest reasons for discontinuing the assigned drug.
Methods
The study sample (146,506; year 2008), representative of the general population, was based in the province of Lecco, Northern Italy. 15, 16 The details of the study design are given elsewhere 15, 16 and are summarized here. In Italy, the diagnosis of epilepsy is confirmed by a neurologist who also takes the responsibility to start, and where needed, to change or stop the treatment. The individual is then followed by his/her general practitioner (GP) to obtain drugs free of charge. One hundred twenty-three GPs (47% of those active in the province) were invited to identify people with epilepsy in their practice's list who had lived in the area for at least 1 year between January 1, 2000 and December 31, 2008 . The medical records of all these individuals in the practice, and if available, in other in-and outpatient facilities such as hospitals, nursing homes, and outpatient clinics were reviewed. Epilepsy diagnosis was based on a history of two or more unprovoked seizures at least 24 h apart 17 and confirmed by a neurologist. People with acute symptomatic seizures, neonatal seizures, single unprovoked seizures, and paroxysmal nonepileptic events were excluded. For each eligible case, data were collected on demographics (date of birth, sex), predominant seizure types, 18 date of diagnosis, epilepsy syndrome, 19 and number and type of drugs used since the beginning of treatment. For each AED, details were collected on starting date, maximal maintenance daily dose, and withdrawal date or last follow-up date, whichever came earlier. If the drug was discontinued, reasons for discontinuation (ineffectiveness, adverse events, terminal remission, or other) were recorded. As the study period preceded the new epilepsies classification scheme, 20 the 1989 classification 19 was used. As detailed information was not available in all cases, seizures and syndromes were classified using broad categories. Seizures were classified as focal, generalized, or unclassifiable. Syndromes were classified as partial (idiopathic, symptomatic, or cryptogenic), generalized (idiopathic or symptomatic/cryptogenic), undetermined, or special. All data from the GPs, and if needed, from the consulting neurologists (including those outside the study area) were deidentified and filed in a central database by two of us (G.G. and V.C.) who interacted with the GPs, and if required, with the neurologists. Two of us (E.Be. and G.E.) revised the information included in the database to confirm the appropriateness of the indications of all drugs assigned to each individual during the disease course.
Prevalence and incidence of epilepsy and of drug-resistant epilepsy, and prognostic patterns in the same study population have been previously reported elsewhere. 15, 16 Statistical analyses were performed using SAS (version 9.2; SAS Institute, Cary, NC, U.S.A.). Descriptive statistics are presented as counts and percentages. Administration frequencies and cause-specific withdrawal frequencies were calculated for each active principle and by prescription order. AEDs were also grouped in two classes: old and newer (marketed before and after 1990). Old drugs included barbexaclone, carbamazepine, clobazam, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproate, and valpromide; newer drugs included gabapentin, levetiracetam, lamotrigine, oxcarbazepine, pregabalin, tiagabine, topiramate, vigabatrin, and zonisamide.
To account for competing risks, cumulative probabilities of AED withdrawal from specific causes over 20 years from treatment start were estimated using cumulative incidence functions. The cumulative probability of cause-specific AED withdrawal was calculated for the first, second, and third AED, for the most common AEDs (i.e., those used by >100 people), and for new and old AEDs separately. Differences in the cumulative incidence functions between new and old AEDs were assessed using Gray's test. 21 For the • In the majority of people, epilepsy can easily be controlled with any of the available compounds even after long follow-up periods first AED, the cumulative probability of withdrawing for terminal remission (i.e., seizure freedom for at least 2 years at last follow-up) while still on treatment was also evaluated.
The association between drug discontinuation and sex, age at diagnosis (<15, 15-64, 65+ years), seizure type (focal, generalized, unclassifiable), duration from first seizure to diagnosis, and epilepsy syndrome (idiopathic, cryptogenic/symptomatic, special/undetermined) was assessed using the Cox proportional hazards function. Models for the most commonly used AEDs were adjusted for the number of drugs previously taken. Results were presented as hazard ratios (HRs) with 95% confidence intervals (CIs). Missing data were handled using the listwise deletion method.
The study was approved by the Ethics Committee of the Provincial Hospital of Lecco (Protocol 2011-003428-11). Local Health Service authorization was obtained to collect deidentified data from the GPs. In <5% of cases, the GPs needed to collect additional information from individuals, after informed consent. All the data were managed according to the current Italian privacy rules.
Results
The study sample consist of 747 people with epilepsy aged 11 months through 94 years and followed for a total of 11,045.5 person-years (mean = 14.8 years, interquartile range = 4.5-22.5). Clinical characteristics are provided in Table 1 ; 731 people (98%) were treated with at least one AED.
The use of each compound as first, second, third, or fourth to ninth AED is shown in Table 2 . The three AEDs most commonly used as first drug were valproate, carbamazepine, and phenobarbital, and the same drugs were also the commonest second option. The third option included, in decreasing order, carbamazepine, levetiracetam, and topiramate.
The commonest reasons for drug withdrawal were, in decreasing order, terminal remission, ineffectiveness, and adverse events. Table 3 shows the reasons for withdrawal with reference to the sequence of drug assignment. For the first AED, the main reasons for withdrawal were terminal remission, followed by ineffectiveness; for the second AED, the main reasons were ineffectiveness, followed by terminal remission; for the third and the fourth AED, the main reason was ineffectiveness, followed by adverse events. Withdrawal for ineffectiveness increased from the first to the seventh drug, whereas withdrawal for terminal remission decreased progressively after the first drug. Adverse events showed a moderate increase from the first to the last assigned drugs.
Reasons for drug withdrawal for each AED are provided in Table 4 . The percentages of withdrawal of carbamazepine, phenobarbital, and valproate due to ineffectiveness were in general lower than the percentages reported for other AEDs.
Cumulative probabilities and predictors of withdrawal of the first, second, and third AED
First AED
The cumulative probability of withdrawal of the first AED for ineffectiveness increased from 2.9% at 1 year to 12.6% at 20 years (Table S1 ). The only predictor was age at diagnosis; compared to those aged <15 years, those in the 15-64-year group were less likely to withdraw due to ineffectiveness (HR = 0.46, 95% CI = 0.28-0.75), whereas those in the oldest group showed no significant differences (HR = 1.26, 95% CI = 0.61-2.59). The cumulative probability of withdrawing the first AED for terminal remission increased from 1.0% at 1 year to 20.0% at 20 years. The variables associated with first AED withdrawal due to seizure freedom were age at diagnosis, sex, and epilepsy syndrome. Compared to those aged <15 years, those in the 15-64 year group were less likely to withdraw the drug (HR = 0.58, 95% CI = 0.40-0.86), whereas those in the oldest group had a similar HR, although this was not statistically significant. Females had a lower probability than males of withdrawing the drug (HR = 0.56, 95% CI = 0.39-0.82). Those with cryptogenic/symptomatic epilepsies (HR = 0.43, 95% CI = 0.29-0.63) had a lower probability of withdrawing the drug than those with idiopathic epilepsies. The cumulative probability of withdrawing the first drug for adverse events was 0.5% at 1 year and increased to 3.3% at 20 years. The probability of withdrawing the first drug for other reasons was 0.2% at 1 year and 6.6% at 20 years. Predictors for adverse events and other reasons were not assessed, due to the small numbers. No significant differences were observed between old and new AEDs given as first treatment (Table S2) . Four hundred sixty people never withdrew the first antiepileptic treatment, and 224 of them (50.9%) started a period of remission lasting until the end of follow-up. The cumulative probability of either withdrawing the first AED for seizure freedom or achieving sustained remission while still on treatment was 23.1% at 1 year and increased to 48.0% at 20 years.
Second AED
The cumulative probability of withdrawing the second drug at 20 years for ineffectiveness was 15.8%, for (Table S1 ). The only variable associated with discontinuation of the second AED for ineffectiveness was seizure type; compared to partial seizures, generalized seizures were more likely to lead to drug withdrawal (HR = 2.05, 95% CI = 1.10-3.83). Due to the small number of events, predictors for other reasons for the withdrawal of the second AED were not evaluated. No significant differences were found between old and new AEDs (Table S2) .
Third AED
The cumulative probability of withdrawing the third AED at 20 years for ineffectiveness was 39.3%, for adverse events 8.0%, for seizure freedom 4.3%, and for other reasons 5.0% (Table S1 ). Due to the small numbers, predictors for the third AED withdrawal were not assessed. The comparison between old and new AEDs showed no significant differences (Table S2) .
Cumulative probabilities and predictors of withdrawal of the most commonly used AEDs
At 20 years, the cumulative time-dependent probability of withdrawal of carbamazepine for ineffectiveness was 10.8%. The corresponding values were 13.5% for phenobarbital and 12.3% for valproate (Fig. 1A) . The 20-year probability of withdrawal for terminal remission was 12.9% for carbamazepine, 14.8% for phenobarbital, and 27.4% for valproate (Fig. 1B) .
Predictors of withdrawal due to ineffectiveness were seizure type for carbamazepine and age for phenobarbital. No predictors were found for valproate. Generalized seizures were more likely than partial seizures to lead to withdrawal of carbamazepine for ineffectiveness (HR = 3.07, 95% CI = 1. 35-6.98 ). Individuals in the 15-64-year group had a lower probability of withdrawing phenobarbital due to ineffectiveness than the youngest age group (HR = 0.24, 95% CI = 0.11-0.54), whereas those in the oldest group had a similar HR, although this was not statistically significant.
Variables associated with drug withdrawal due to seizure freedom were sex for carbamazepine and age, sex, and syndrome for valproate. No predictors were found for phenobarbital. Females had a lower probability of withdrawing carbamazepine for seizure freedom than males (HR = 0.47, 95% CI = 0.22-0.99). Compared to people in the <15-year group, those aged 15-64 years were less likely to withdraw valproate due to ineffectiveness (HR = 0.30, 95% CI = 0.13-0.70), whereas those in the oldest group had a similar HR, although this was not statistically significant; females had a lower probability of withdrawing the drug than males (HR = 0.52, 95% CI = 0.30-0.91); compared with idiopathic epilepsies, those with cryptogenic/symptomatic epilepsies were less likely to have drug withdrawal (HR = 0.35, 95% CI = 0.19-0.65). Due to the small number of events, cumulative probabilities, and predictors of carbamazepine, valproate, and phenobarbital withdrawal for adverse events and other reasons were not assessed.
Discussion
People in our cohort, a representative sample of people with epilepsy in a defined area of Northern Italy, have used a large number of AEDs over a 15-year period. However, during this time, the three most common drugs given at the start of treatment were valproate, carbamazepine, and phenobarbital, and only 10% of people started treatment with a new AED. Terminal remission was the commonest explanation for discontinuation of the first drug (20% at 20 years), followed by lack of efficacy (12.6%). Withdrawal of the first drug for adverse events was only 0.5% at 1 year and increased to 3.3% at 20 years. Whereas the discontinuation of a drug for terminal remission tended to decrease with AED order, treatment termination for ineffectiveness and for adverse events tended to increase, although clear trends could not be detected because of the small samples at the highest rankings. The reasons for drug withdrawal varied with age, sex, and disease characteristics.
The probability of retaining the first drug in the treatment schedule and starting a period of remission lasting until the end of follow-up, or of stopping the first treatment for terminal remission, was high, 48% at 20 years. Others found that the proportion of seizure-free individuals on the first AED ranged from 5.4% to 62% 3, 4, 12, [22] [23] [24] ; 63% of our patients never withdrew the first AED, and 51% of them started a period of remission lasting until the end of follow-up. This finding supports the concept that in clinical practice the majority of people with epilepsy can be easily controlled with any of the available compounds even after long followup periods.
In our study, the cumulative probability of discontinuing the first drug at 12 months for lack of efficacy or adverse events was only 3.4%. Our findings are fairly similar to the results of a Lebanese study of people with newly diagnosed focal epilepsy, which found a 12-month retention rate of 93.6%. 25 Our data only partly agree, however, with other long-term follow-up studies. In the U.K. National General Practice Study of Epilepsy 12 the first assigned drug was discontinued for lack of efficacy in 21% of cases (compared to our 12.6%), but the discontinuation rate for adverse events was 11.5% (compared to 3.3% in our study). This difference may be explained by the use of carbamazepine, phenytoin, valproate, or phenobarbital in 96% of the U.K. cases as compared to 87% in our cohort. The use of fairly low daily doses for some drugs in our study (see Table S3 ) could be another explanation. No differences were found in retention rates when comparing old and new AEDs. Our findings are in keeping with a study in children 26 but differ from a study in older adults 27 in which the 12-month retention rates ranged from 12.5% (oxcarbazepine) to 90% (valproate). In this latter study, however, the rates were calculated in people with refractory epilepsy.
When comparing drugs in our study, differences in retention were seen. Discontinuation for lack of efficacy was most common with c-aminobutyric acidergic drugs, whereas discontinuation for adverse events was mostly seen with topiramate, phenytoin, carbamazepine, and levetiracetam, in decreasing order. These findings are not unexpected, although the rates differ from those of other reports [28] [29] [30] [31] [32] [33] on account of differing prescribing patterns and different populations at risk.
People in our cohort taking carbamazepine, valproate, or phenobarbital discontinued the assigned treatment for adverse events in 5.6%, 1.1%, and 2.8% of cases, respectively. Our rates are significantly lower than those reported by others (carbamazepine, valproate, and lamotrigine stopped in 27%, 13%, and 10% of cases, respectively). 3 
Figure 1.
Cumulative incidence functions for withdrawal of carbamazepine, phenobarbital, and valproate, for ineffectiveness (A) and terminal remission (B). CBZ, carbamazepine; PB, phenobarbital; VPA, valproate. Epilepsia ILAE Possible explanations for this difference are the source population, as the Scottish study was not population-based, and the use of different daily doses.
Children and elderly subjects tended to stop the first drug mostly for lack of efficacy and, less frequently, due to terminal remission. Childhood and adolescent syndromes less responsive to the current treatments and the need to resort to complex therapeutic regimens in people with comorbidities are possible explanations.
The lower rates of treatment withdrawal due to terminal remission in women than in men likely reflects the higher proportion of females in the age class <15 years (59% vs. 41% of male children) who continued the first treatment, perhaps because of the fear of withdrawal in a period of hormonal and emotional changes. As expected, people with idiopathic epilepsies and/or generalized seizures were most likely to respond to the assigned treatments.
The study has strengths and limitations. The major strengths are the population base, the fairly large sample size, and a long follow-up. In this regard, our findings apply to the general epilepsy population in which, by definition, severe epilepsies are less frequent than in secondary and tertiary referral centers. The major limitation is the uncontrolled setting. We do not know whether a drug was discontinued after having been given at the highest tolerated dose. Our aim, however, was to explore treatment changes as performed in clinical practice, where the selected daily dose generally represents a compromise between seizure control, adverse events, and individual preference. Another limitation is the time frame during which we started the follow-up. To include people with newly diagnosed epilepsy in the cohort with reasonable follow-up, we started the observation at a time in which mainly older AEDs were available. We are thus uncertain whether our findings apply to cohorts starting treatment with a new AED. In keeping with our findings, however, there is no evidence from more recent reports [34] [35] [36] [37] [38] [39] [40] [41] that new AEDs have advantages over older compounds. Thus, we do not expect significant differences in other therapeutic contexts. Furthermore, the cumulative time-dependent probability of withdrawal of AEDs other than carbamazepine, phenobarbital, and valproate was not assessed because of small numbers. The limited sample size can also explain some nonsignificant correlations between demographic and clinical variables and drug withdrawal. Lastly, we did our best to verify whether the indication for each drug was appropriate. However, we cannot entirely exclude that drug failure was due to incorrect use of a given drug in a given individual.
In conclusion, the majority of people with epilepsy living in a community and followed for a prolonged period of time remain treated with the first assigned drug. Seizure remission is the main reason for drug discontinuation, followed by lack of efficacy and adverse events. Withdrawal of the first drug for ineffectiveness and for adverse events tends to increase by AED order, while decreasing for terminal remission. Withdrawal of the first AED for ineffectiveness can be predicted by age at diagnosis, whereas withdrawal of the second drug is predicted by seizure type, and reflects the predominance of more severe epilepsy syndromes in younger individuals. These findings can help the practicing physician to predict the response to the assigned treatment at diagnosis and when a treatment change is required. Table S2 . Cause-specific cumulative probabilities of withdrawal of the first, second, and third drug, by old and new antiepileptic drugs. Table S3 . Drug daily doses (median and range) of first antiepileptic drug given to children (<15 years old; A) and adults (≥15 years old; B).
